Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amy Flaxman

Senior Post-Doctoral Immunologist

I have always been interested in translational research – how can what I am doing at the bench have an impact at the bedside? After studying Molecular and Cellular Biology at the University of Bath, I worked for several years in academia and industry building my laboratory skills base. I came to the Jenner Institute and undertook my DPhil studies investigating the impact of S. aureus colonisation and how this impacts vaccination. The aim was to study how pre-existing exposure to the bacterium can impact on subsequent vaccination against it.

For my post-doctoral research I have worked on both pre-clinical studies developing vaccines for outbreak pathogens, such as Ebola, and clinical trials for pre-erythrocytic Malaria and outbreak pathogens, including MERS and Ebola.

I am continuing my research in Teresa Lambe’s group working on immune responses to the Oxford ChAdOx1-nCoV vaccine for SARS-CoV-2 currently in Phase III clinical trials. I lead the lab team carrying out antibody testing post-vaccination. Here, I am interested in the differences in antibody responses induced over time with different doses of vaccine, in different age groups and how this changes with administration of a booster vaccine. We are also interested in cross-reactive immune responses to other circulating coronaviruses which cause mild disease.